Evaluation of a New Silicone Hydrogel Contact Lens
- Conditions
- Myopia
- Interventions
- Device: Air Optix AquaDevice: Test lens
- Registration Number
- NCT01309880
- Lead Sponsor
- Bausch & Lomb Incorporated
- Brief Summary
The objective of this study is to determine the clinical feasibility and to evaluate the product performance of investigational contact lenses developed by Bausch + Lomb.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
- Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
- Be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand.
- Have worn gas permeable (GP) contact lenses within last 30 days or polymethylmethacrylate (PMMA) lenses within last 3 months.
- Any systemic disease affecting ocular health.
- Using any systemic or topical medications that will affect ocular physiology or lens performance.
- An active ocular disease, any corneal infiltrative response or are using any ocular medications.
- Any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.
- Allergic to any component in the study care products.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Air Optix Aqua Air Optix Aqua Ciba Vision daily wear contact lens Test Lens Test lens Investigational silicone hydrogel contact lens
- Primary Outcome Measures
Name Time Method Visual Acuity Dispensing & 1-week follow up Distance high contrast logMAR lens visual acuity (VA) between the Air Optix Aqua lens and the Test Lens at Dispensing and at 1-Week Follow-up.
- Secondary Outcome Measures
Name Time Method Slit Lamp Findings 1 week Measured on a scale of 0-4 where 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe for edema, microcysts, corneal staining, limbal injection, bulbar injection, upper lid tarsal conjunctival abnormalities, corneal neovascularization and corneal infiltrates.
Comfort 1 Weeks At 1-Week Follow-up, participants rated lens comfort on a scale of 0 to 100, with 100 being the most favorable score.
Trial Locations
- Locations (1)
Bausch & Lomb, Incorporated
🇺🇸Rochester, New York, United States